#USA #New York #Lucid Diagnostics #EsoGuard® #Esophageal Test

Lucid Diagnostics Gains Coverage for EsoGuard® Testing

Lucid Diagnostics Inc., a leader in cancer prevention through medical diagnostics, has made a significant stride in enhancing accessibility to its innovative EsoGuard® Esophageal DNA Test. On August 5, 2026, the company announced that Concert, a healthcare technology firm recently acquired by Lyric, established a positive coverage policy for this essential screening tool, effective from July 2026. This advancement is expected to improve early detection of esophageal precancer and cancer among at-risk patients.

The Importance of EsoGuard®

EsoGuard® is designed specifically for individuals with gastroesophageal reflux disease (GERD), a condition that significantly increases the risk of developing esophageal precancer and cancer. By employing a non-invasive method, the test allows healthcare providers to collect samples easily using the EsoCheck® Esophageal Cell Collection Device, aiming for timely intervention and the prevention of severe health consequences.

Dr. Lishan Aklog, Chairman and CEO of Lucid Diagnostics, expressed his enthusiasm about the new coverage policy, stating, "Securing this coverage policy is another significant step toward broad commercial coverage of EsoGuard, as Concert's policies drive adoption by the health plans it serves." This marked improvement in policy recognition is pivotal as it not only validates their rigorous clinical evidence but also encourages multiple health plans to adopt the testing policy.

Coverage Expansion and Patient Access

The policy highlights the necessity for EsoGuard® among patients meeting the American College of Gastroenterology (ACG) screening criteria, underscoring the diagnostic tool's medical importance. As more Concert client health plans embrace this coverage, Lucid Diagnostics remains committed to expanding access to precancer testing across the nation. This is vital for patients who are at heightened risk but may have previously faced barriers to receiving such critical screenings.

The significance of this development cannot be overstated. In a market that is increasingly focused on preventive healthcare, having support from major health plans marks a triumphant moment for Lucid Diagnostics and the patients they aim to serve. There is hope that with increased awareness and adoption, EsoGuard® can play a crucial role in reducing the incidence of esophageal cancer, which often goes undetected until it reaches advanced stages.

Future Perspectives

Lucid Diagnostics is not resting on its laurels. The company is actively engaging with commercial insurers and their benefit managers, with the goal of further expanding the reach of EsoGuard®. As they continue to strengthen their relationships and advocate for patient access, there is an optimism that additional health plans will recognize the value and necessity of this groundbreaking test.

As discussions regarding healthcare policy continue to evolve, Lucid Diagnostics stands at the forefront of innovation and preventative care in cancer diagnostics, striving to make a profound impact on patient health outcomes. With the EsoGuard® Esophageal DNA Test gaining traction, Lucid is well-positioned to be a catalyst for change in early cancer detection and prevention strategies going forward.

For more information about Lucid Diagnostics and the EsoGuard® test, please visit their website at www.luciddx.com.